Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

SA Transcripts158.52K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines February 17, 2026 12:00 AM EST Company Participants Koichi KinoToru Kimura - President, CEO & Representative DirectorYumi Sato - Managing Exe. Officer of Research & Dev. Div. Senior VP and Head of Research & Development DivisionMasashi Murata Conference Call Participants Shinichiro Muraoka - Morgan Stanley, Research DivisionSeiji Wakao - JPMorgan Chase & Co, Research DivisionKazuaki Hashiguchi - Daiwa Securities Co. Ltd., Research DivisionHiroshi Wada - SMBC Nikko Securities Inc., Research DivisionTomiyamaShimizuMisumiOkadaHiroaki HashimotoSakaguchiKuriyama Presentation Koichi Kino We will now begin the R&D meeting of Sumitomo Pharma Company Limited. Thank you very much for joining us today. First, I will explain our R&D progress, basic policy and two major oncology products using the presentation material available on our website, followed by a question-and-answer session. The end time is scheduled for 15:40. In attendance today are Mr. Kimura, Representative Director, President and CEO, Mr. Sakai, Representative Director, Executive Vice President; Ms. Sato, Managing Executive Officer; and Mr. Murata, Global Strategy Oncology Lead. First, Mr. Kimura will say a few words. Toru KimuraPresident, CEO & Representative Director Thank you very much for attending our R&D presentation today. I would like to say a few words at the opening of the meeting. Last Friday, the 13th, the agenda for the Regenerative Medicine Products and Biologics Technology Subcommittee of the Pharmaceutical Affairs Council of the Ministry of Health, Labor and Welfare, scheduled to meet on February 19, was announced. Non-autologous iPS cell-derived dopamine neural progenitor cells for which we have applied for approval were also on the agenda. Since the product name AMCHEPRY is to approved by the subcommittee, we had not disclosed it before. But on the 13th, we disclosed that this is our product. The subcommittee will discuss the approval of AMCHEPRY, and then a final decision will